Therapeutic Areas
With more than two decades of experience in the clinical research industry, Everest has experience in more than 30 different therapeutic areas. Click on the areas below to learn about our expertise in each TA.
Therapeutic Areas
Oncology Neurology Respiratory Immunology Infectious Disease Ophthalmology Metabolic CardiologyOncology
Our Oncology expertise spans both solid tumors and hematologic malignancies, with a strong focus on Immuno-Oncology approaches, including checkpoint inhibitors, cancer vaccines, oncolytic viruses, and cellular therapies. We support development from first-in-human through late-phase trials across diverse tumor types. Oncology trials represent approximately 30% of our portfolio, and more than half of those studies are in Phase 1, including complex cell and gene therapy. We can also support studies with rare populations, dose escalation/expansion, and a range of innovative therapies and complex study designs.
160+
studies in the past 4 years
Experienced indications include:
Lung cancer
Breast cancer
Gastrointestinal cancer
Liver cancer
Prostate cancer
Skin cancer
Leukemia and Lymphoma
Myeloma
Myeloproliferative Neoplasms
Hematological Malignancies
Advanced Solid Tumors
Neuroendocrine Tumors
Head and Neck Cancers
Ovarian Cancer
Cervical Cancer
Endometrial (Uterine) Cancer
Bladder Cancer
Renal (Kidney) Cancer
Testicular Cancer
Thyroid Cancer
Sarcomas (e.g., soft tissue, bone)
Central Nervous System (CNS) Tumors (including glioblastoma, medulloblastoma)
Pancreatic Neuroendocrine Tumors
Pediatric Solid Tumors (e.g., neuroblastoma, Wilms tumor)
CAR-T Cell Therapy-Related Indications
Rare Cancers and Tumor-Agnostic Indications (e.g., NTRK fusions, MSI-H/dMMR tumors)
Neurology/CNS
Everest has deep expertise in central nervous system (CNS) clinical research across neurological, neurodegenerative, psychiatric, movement, and neurodevelopmental disorders. We have supported trials from early to late phase, including rare CNS indications and hard-to-enroll populations. We bring a deep understanding of CNS pathologies, trial logistics, and regulatory expectations to each study. This breadth of experience allows us to deliver tailored, high-quality support across the full spectrum of CNS clinical development.
105+
CNS studies in the previous 4 years
Our past experience in CNS indications include:
Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)
Rett Syndrome
Batten Disease
Hunter Syndrome
Spinal Muscular Atrophy
Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS)
Mitochondrial Myopathy
Depression
Anxiety
Bipolar Disorder
Schizophrenia
Psychosis and Cognitive Impairment
PTSD
Cervical Dystonia
Neurogenic Orthostatic Hypotension
Autism Spectrum Disorder
Neurocognitive Outcomes of Children with Phenylketonuria
Acute Ischemic Stroke
Respiratory
Our work in Respiratory clinical development includes both early- and late-phase trials, spanning acute and chronic respiratory conditions as well as infectious respiratory diseases. We also bring cross-functional expertise in therapeutic areas that overlap with oncology and immunology, including lung cancer and autoimmune-related lung disease. This diverse portfolio reflects our ability to navigate complex respiratory trials with flexible, high-quality support tailored to the unique demands of respiratory clinical development.
80+
studies in the past 4 years
Top indications include:
Asthma
Chronic Obstructive Pulmonary Disease (COPD)
Idiopathic Pulmonary Fibrosis
Respiratory Viruses
Cystic Fibrosis
Interstitial Lung Disease
Scleroderma
Progressive Pulmonary Fibrosis (PPF)
Lung Cancer
Infectious Disease
We have extensive expertise in conducting complex infectious disease clinical trials across a broad spectrum of viral, bacterial, and parasitic pathogens. Our experience spans all clinical development phases (I–III) and includes both interventional and observational designs.
During the 2020 pandemic we supported pivotal COVID-19 vaccine and therapeutic programs, including large-scale multinational Phase II/III efficacy trials, monoclonal antibody prophylaxis and treatment studies, and real-world evidence generation for diagnostic devices.
Experienced indications include:
COVID-19 (treatment, prophylaxis, vaccine, diagnostics)
SARS-CoV-2 diagnostic assays (antigen test kits, multiplex flu + COVID assays)
Influenza A & B (combined respiratory diagnostics)
Respiratory Syncytial Virus (RSV)
HIV infection (therapeutics + vaccine studies)
Hepatitis B virus (HBV) infection, including HBV-related hepatocellular carcinoma
Hepatitis C virus (HCV) infection
Recurrent Clostridium difficile infection (rCDI)
Complicated urinary tract infection (cUTI)
Acute uncomplicated pyelonephritis (AP)
Complicated intra-abdominal infection (cIAI)
Hospital-acquired bacterial pneumonia (HABP)
Ventilator-associated bacterial pneumonia (VABP)
Onchocerciasis (river blindness)
Post-exposure prophylaxis for high-risk populations
Immunology
We have broad experience supporting clinical trials in the field of immunology, encompassing autoimmune, inflammatory, and immune-mediated disorders. Our work spans all phases of development, from early Phase 1 through Phase 3 trials, as well as long-term follow-up studies, NDA submission support, and registry or investigator-sponsored studies. We have supported a range of therapeutic modalities, primarily biologics and small molecules, with additional experience in NK-cell therapy.
Top indications:
Ulcerative Colitis
Peanut Allergy
Celiac Disease
Rheumatoid Arthritis
Generalized Pustular Psoriasis (GPP)
Palmoplantar Pustulosis (PPP)
Alopecia Areata
Atopic Dermatitis
Lupus Nephritis (Class III or IV)
Primary Membranous Nephropathy (PMN)
IgA Nephropathy
Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Hypereosinophilic Syndrome (HES)
Eosinophilic Esophagitis
Eosinophilic Gastritis
Severe Eosinophilic Asthma
Severe Allergic Asthma
Metabolic
Everest has significant and wide-ranging experience in the Metabolic therapeutic area, supporting clinical development from early-phase trials through global Phase 3 programs and long-term follow-ups. Our teams have provided full-service and functional service support across a variety of drug classes, including biologics, small molecules, medical devices, and cell therapies. We have supported trials in high-prevalence conditions such as Type 2 Diabetes, Obesity, and Dyslipidemia, as well as rarer and more complex metabolic disorders. Our experience also includes trials focused on key metabolic endpoints such as HbA1c reduction, cardiovascular outcomes, weight loss, and morbidity/mortality reduction.
66+
studies in the past 4 years
Indications include:
Type 2 Diabetes Mellitus (including HbA1c reduction and cardiovascular outcomes)
Type 1 Diabetes (including hypoglycemia and continuous glucose monitoring)
Obesity
Diabetic Foot Infections
Hypothyroidism
Acromegaly
Dyslipidemia
Severe Hypertriglyceridemia
Hypertriglyceridemia with Cardiovascular Disease
Familial Chylomicronemia Syndrome (FCS)
Idiopathic Pediatric Growth Hormone Deficiency (PGHD)
Congenital Adrenal Hyperplasia (Classic and General)
Central Precocious Puberty
Primary Biliary Cholangitis
Nonalcoholic Steatohepatitis (NASH)
Heart Failure with Preserved Ejection Fraction (HFpEF) and Obesity
Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS)
Familial Hypercholesterolemia
Cardiovascular Disease with Metabolic Comorbidities
Cardiology
We bring extensive clinical expertise across a broad range of cardiovascular indications. Our team has successfully executed early- and late-phase clinical trials, with particular strength in large, multicenter Phase III programs.
Our experience spans critical areas of cardiovascular disease management, including Heart Failure, Atherosclerotic Cardiovascular Disease (ASCVD), Acute Coronary Syndrome (ACS), and Hypertriglyceridemia, as well as related metabolic conditions that intersect with cardiovascular risk.
Our team brings a thorough understanding of cardiovascular pathophysiology, study design, and regulatory requirements to every trial. This comprehensive experience enables us to provide tailored, high-quality support across the full spectrum of cardiovascular clinical development.
Indications include:
Atrial Fibrillation
Acute Coronary Syndrome
Heterozygous Familial Hypercholesterolemia
Hypertriglyceridemia
Atherosclerotic Cardiovascular Disease
Heart Failure/Acute Heart Failure
Chronic Advanced Ischemic Heart Failure
Myocardial Infarction / ST-elevation Myocardial Infarction
Prevention of Venous Thromboembolism (VTE)
Ophthalmology
Everest has supported many ophthalmology clinical trials across all phases and global regions, with particular depth in age-related macular degeneration diabetic eye diseases, and rare inherited retinal disorders. We have contributed to studies targeting both exudative (“wet”) and non-exudative (“dry”) ophthalmic conditions, demonstrating our ability to navigate the distinct challenges of each. Our work spans a wide range of therapeutic modalities including biologics, small molecules, gene therapies, and medical devices.
70+
studies in the past 4 years
Indications include:
Diabetic Macular Edema (DME)
Neovascular (Wet) Age-Related Macular Degeneration (wAMD/nAMD)
Geographic Atrophy
Dry Age-Related Macular Degeneration
Diabetic Retinopathy (Non-Proliferative and Proliferative)
Macular Neovascularization secondary to AMD
Stargardt Disease
Retinitis Pigmentosa (including X-linked)
Leber’s Hereditary Optic Neuropathy
Open-Angle Glaucoma
Ocular Hypertension
Dry Eye Disease
Presbyopia
Myopia
Hyperopia
Astigmatism
Rare Disease
Everest has extensive expertise in Rare Diseases, providing comprehensive support for clinical trials and research across all phases. We have particular strength in Genetic and Hereditary Conditions, CNS/Neurology, Hematology, Immunology, and Endocrinology. Our experience spans hundreds of sites and thousands of patients across North America, Europe, Asia, South America, and Oceania. Everest has supported a wide range of therapeutic modalities—including gene therapies, biologics, and small molecules—demonstrating our versatility and depth in the rare disease space.
90+
studies in the past 4 years
Indications include:
Adrenomyeloneuropathy (AMN)
Gaucher Disease (Types 1, other)
Epilepsy (Lennox-Gastaut Syndrome, SCN2A Encephalopathy, Developmental and Epileptic Encephalopathy)
Hereditary Angioedema
Acromegaly
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP, Pediatric CIDP)
Hunter Syndrome (MPS II, Neuronopathic MPS II)
Rett Syndrome
Batten Disease (CLN5, others)
Barth Syndrome
Central Precocious Puberty
Essential Thrombocythemia
Fabry Disease (incl. renal impairment, amenable GLA variants)
Familial Adenomatous Polyposis (FAP)
Generalized Pustular Psoriasis / Palmoplantar Pustulosis
Hemophilia B
Huntington’s Disease
Ichthyosis
Idiopathic Growth Hormone Deficiency
Leber’s Hereditary Optic Neuropathy
Mitochondrial Myopathy
Myasthenia Gravis
Myelofibrosis
Neurofibromatosis Type 1, Plexiform Neurofibroma
Phenylketonuria (PKU)
Pompe Disease
Positive Membranous Nephropathy (aMN)
Cell and Gene Therapy
We bring deep operational and scientific expertise to the clinical development of advanced therapy medicinal products (ATMPs), including gene therapies, CAR-T, TCR-T, and other autologous and allogeneic cell-based approaches. Our experience spans therapeutic areas such as Oncology, Cardiovascular, Opthalmology, Autoimmune, Metabolic and Rare Diseases and includes early-phase first-in-human trials through pivotal multicenter studies, with a focus on the unique complexities of CGT research.
100+
studies in the past 4 years
Experienced indications include:
Advanced Solid Tumors
Advanced Hematological and Solid Tumor Malignancies
B-Cell Malignancies (including Lymphoma)
CD19+ B-cell Lymphoma (including CLL, SLL)
Classical Hodgkin Lymphoma
Gastric, GEJ, Esophageal, or Pancreatic Adenocarcinoma
Hepatitis B Virus–related Hepatocellular Carcinoma
Locally Advanced or Metastatic Breast Cancer
Multiple Myeloma (including Relapsed/Refractory)
Non-Hodgkin Lymphoma (various subtypes)
Relapsed/Refractory Acute Myeloid Leukemia (AML)
High-risk Myelodysplastic Syndromes (MDS)
Relapsed/Refractory CD20+ B-Cell Non-Hodgkin Lymphoma or CLL
Small Cell Lung Cancer
T-cell Malignancies (including T-cell NHL)
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Nasopharyngeal Carcinoma (NPC)
Batten Disease (Neuronal Ceroid Lipofuscinosis Subtype 5)
Epilepsy (Mesial Temporal Lobe Epilepsy, SCN2A Encephalopathy)
Fabry Disease (neurological involvement)
Gaucher Disease (neurological variants)
Huntington's Disease
Parkinson's Disease
Rett Syndrome
Stargardt Disease (inherited retinal dystrophy)
Idiopathic Inflammatory Myopathies (IIMs)
Systemic Sclerosis (SSc)
Rheumatoid Arthritis (RA)
Sjögren’s Disease (SjD)
Lupus Nephritis (Class III/IV) & refractory Systemic Lupus Erythematosus
B-cell associated autoimmune diseases
Adrenomyeloneuropathy (AMN)
Duchenne Muscular Dystrophy (DMD)
Neuronopathic MPS II (Hunter Syndrome)
X-Linked Severe Combined Immunodeficiency (XSCID)
Type 1 Diabetes with hypoglycemia
Diabetic Macular Edema (DME)
Dry Age-Related Macular Degeneration (AMD)
Macular Neovascularization secondary to AMD (nAMD)
Neovascular (wet) AMD
Retinitis Pigmentosa (including X-linked)
Acute Ischemic Stroke (AIS)
Refractory Angina / Cardiovascular Disease
End-Stage Liver Disease
COVID-19 or ARDS
Medical Device
Everest has supported a broad range of medical device clinical studies across therapeutic areas including ophthalmology, cardiology, respiratory disease, neurology, infectious disease, urology, and women's health. Our experience spans global observational, interventional, and real-world evidence studies across all phases, including work on diagnostic test kits for COVID-19 and influenza, heart valves for tricuspid regurgitation, drug delivery devices for COPD, intraocular and contact lenses for various vision conditions, and neuromodulation devices for Alzheimer's disease. This diversity highlights Everest’s versatility in managing complex device trials from feasibility through post-marketing.